Navigation Links
State stem cell research funding agency awards $20 million to UCI, StemCells Inc.

Irvine, Calif., July 26, 2012 Efforts to begin human clinical trials using stem cells to treat cervical spinal cord injury in the U.S. received a $20 million boost Thursday, July 26, from the state's stem cell research funding agency, the California Institute for Regenerative Medicine.

The award will be shared by Aileen Anderson and Brian Cummings, associate professors of physical medicine & rehabilitation at UC Irvine's Sue & Bill Gross Stem Cell Research Center, and Nobuko Uchida of StemCells Inc. in Newark, Calif. Anderson and Cummings proved that transplanting human neural stem cells discovered and developed by Stem Cells, Inc. into rodents with thoracic spinal cord injury could restore mobility. The CIRM award announced Thursday will fund the collection of data necessary to establish human clinical trials in the U.S.

"Our therapeutic approach is based on the hypothesis that transplanted human neural stem cells integrate into the injured spinal cord to repair the protective myelin sheath and spinal circuitry," Anderson said. "Any therapy that can partially reverse some of the effects of spinal cord injury could substantially change the quality of life for patients by altering their dependence on assisted living and medical care."

CIRM's governing board on Thursday gave authorized $150 million for eight teams at five institutions statewide. The projects backed are considered critical to the institute's mission of translating basic stem cell discoveries into clinical cures.

"CIRM's support for UC Irvine's efforts to advance novel stem cell-based therapies for a variety of diseases is extremely gratifying," said Peter Donovan, director of the university's Sue & Bill Gross Stem Cell Research Center. "This latest award for spinal cord treatment holds great promise. We are delighted."

About 1.3 million Americans suffer chronically from spinal cord injuries. In California, nearly 147,000 individuals are living with such damage, which can severely impair the movement, sensation and autonomic function of otherwise healthy people. Recovery from spinal cord injury is often limited, even after aggressive emergency intervention with steroids and surgery, followed by rehabilitation.

"That's crushing for anyone," Anderson noted. "It's very tough for patients and their families. We believe stem cell therapies could provide significant functional recovery, improve quality of life and reduce the cost of care for those with spinal cord injury. That's our goal."

Anderson's and Cummings' laboratory has a long history of collaboration with StemCells Inc. in addressing spinal cord injury, including studies that led to the world's first clinical trial of a neural stem cell therapy for chronic spinal cord injury. This Phase I/II clinical trial, currently under way in Zurich, recently reported positive safety data from the first cohort of treated patients and continues to enroll subjects.

"We are very encouraged by the preliminary results in these volunteers" Cummings said, "and we are excited to receive CIRM funding to enable us to extend this approach to those with cervical injuries and to patients in the U.S."


Contact: Cathy Lawhon
University of California - Irvine

Related medicine news :

1. Men with prostate cancer more likely to die from other causes
2. Wayne State develops better understanding of memory retrieval between children and adults
3. A new route for tackling treatment-resistant prostate cancer
4. President Obama names SF State math professor a top young scientist
5. Surgery Not Best Option for Early Stage Prostate Cancers: Study
6. Reducing Ozone Limits Would Save Lives, Report States
7. SUNY Downstate receives award to develop mobile phone apps for stroke patients and their caregivers
8. Algae extract increases good cholesterol levels, Wayne State research finds
9. Taking tissue regeneration beyond the state-of-the-art
10. Loss of protein SPDEF allows prostate cancer cells to gain foothold at possible sites of metastasis
11. New study finds increase in track-related injuries among youth in the United States
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... Today, Mothers Against Drunk ... roadways has dropped below 10,000 for the first time since 2011. In 2014, there ... According to data released by the National Highway Traffic Safety Administration (NHTSA), 32,675 people ...
(Date:11/25/2015)... ... ... An unlikely combination of recycled plastic shopping bags in ... to have a more dignified and comfortable night’s sleep. , Residents of Friendship ... bags into sleeping mats for the homeless. The project, according to Jeannette ...
(Date:11/25/2015)... CA (PRWEB) , ... November 25, 2015 , ... ... bunion treatment, is offering lower prices in an early celebration of the early ... the promotional price of $29.95 each (normally $33.95 ea). Black Friday promotional pricing ...
(Date:11/24/2015)... ... November 24, 2015 , ... Young patients with a wide variety ... Wolfman and Dr. Kedar S. Lele, who are pediatric dentists in Tucson, AZ ... the WaterLase iPlus 2.0™ system causes minimal discomfort and bleeding to the patient during ...
(Date:11/24/2015)... ... , ... DMG Productions announced that they will feature Aphria, Inc., in an ... Channel. Dates and show times TBA. , Aphria, Inc., is a publicly traded company ... and supplying medical marijuana pursuant to the Marijuana for Medical Purposes Regulations (the “MMPR”). ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... , November 25, 2015 The ... to repeated failure of IVF cycles. After failure of ... dejected and had lost all hopes that she would be able to ... miracle child conceived after failure of over 15 IVF ... (UK) before they decided to take one last attempt with Gaudium ...
(Date:11/24/2015)... CARLOS, Calif. , Nov. 24, 2015 ... a leader in non-invasive genetic testing and ... announced that it will present at the ... in New York on Wednesday, December 2, 2015 at 1:00 p.m. ET.  Matthew ... the Company,s financial results, business activities and ...
(Date:11/24/2015)... TX and VANCOUVER, Nov. 24, 2015 /PRNewswire/ - ... NASDAQ: EPIX ) announced today that the first ... study of EPI-506 as a treatment for metastatic castration-resistant ... and Canada.  --> ... --> In the Phase 1/2 clinical trial, ESSA ...
Breaking Medicine Technology: